GLP-1 drug boom fuels a new wave of health products and retail strategies

The popularity of GLP-1 weight-loss drugs like Ozempic and Wegovy has sparked a surge in related health products. Companies are now offering supplements, specialised foods, and in-store support to help users manage side effects and improve results. Recent studies and retail expansions highlight how the stock market is adapting to this growing trend.

Evolv has released Evolv GLP-1, an oral supplement designed to mimic the body's natural GLP-1 signalling. Clinical trials showed participants taking its core ingredient lost an average of six pounds over two months while keeping lean muscle mass.

GNC has also entered the space with a peer-reviewed paper led by Dr. Brittany Johnson, one of its employees. The research suggests supplements—including multivitamins, vitamin D, omega-3s, protein, and probiotics—can support muscle health and overall wellness for those on GLP-1 therapies. To match this guidance, the retailer has rolled out 'semaglutide support' sections in over 2,300 U.S. stores, offering products to ease common side effects.

Meanwhile, Supergut, a brand selling 'GLP-1 superfoods,' has seen its sales more than triple in the past year. The rise in demand reflects broader stock market today growth, with telehealth providers like LifeMD now offering virtual consultations and pharmacy services for GLP-1 drugs across all 50 states.

The U.S. adult obesity rate has dropped from 39.9% in 2022 to 37.0% in 2025, a shift partly linked to the widespread use of these medications. GNC's push for supplement use alongside GLP-1 treatments signals how businesses are positioning themselves in the expanding marketplace.

With GLP-1 drugs reshaping weight management, retailers and supplement brands are quickly adapting. Products like Evolv GLP-1, GNC's support sections, and Supergut's foods aim to fill gaps in nutrition and side-effect relief. The marketplace's response suggests long-term integration of these therapies into mainstream health routines.